Gene panel testing for breast cancer should not be used to confirm syndromic gene associations.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. FromBreast care (Basel, Switzerland) · 2021
   Article
2. A review on age-related cancer risks in PTEN hamartoma tumor syndrome.Clinical genetics · 2021
   Review
3. Heritability of mammographic breast density.Quantitative imaging in medicine and surgery · 2020
   Article
4. Exon splicing analysis of intronic variants in multigene cancer panel testing for hereditary breast/ovarian cancer.Cancer science · 2020
   Article
5. Increased breast cancer risk in women with neurofibromatosis type 1: a meta-analysis and systematic review of the literature.Hereditary cancer in clinical practice · 2019
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

4 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.